Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management.
OBJECTIVE
To evaluate the use and potential benefit of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) in the management of osteoporosis.


METHODS
Clinical literature accessed through MEDLINE (1994-May 2001) using the key search terms HMG-CoA reductase inhibitors, statins, osteoporosis, and fractures.


RESULTS
Osteoporosis is the most common bone disease, affecting millions of people worldwide and leading to significant morbidity and high expenditures, especially when it is not adequately managed. Recent data have documented a potential association between statin use and improvement in fracture risk profile. Therefore, an evaluation of studies investigating the effect of HMG-CoA reductase inhibitors on bone and fracture risk was conducted.


CONCLUSIONS
Observational studies suggest an association between HMG-CoA reductase inhibitors and reduction in fracture risk. However, large randomized controlled studies are needed to confirm this association.
Coons
James C
JC
University of Virginia Health System, 1205 Swan Lake Dr., Apt. 203, Charlottesville, VA 22902-8236, USA. jccst25@hotmail.com
D015519:Bone Density / Q000187:drug effects*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016239:MEDLINE; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents